| 24.81 Delayed Data As of May 22 |  -0.95 / -3.69%Today’s Change | 24.61 Today|||52-Week Range 50.44 | -14.65% Year-to-Date |
| Why Should You Hold on to Myriad Genetics (MYGN) Stock? May 21 / Zacks.comZAK - Paid Partner Content | Were Invitae's Quarterly Results Really That Bad? May 09 / MotleyFool.com - Paid Partner Content |
| Myriad Genetics Reduced 2019 Guidance, but Is It Really So Bad? May 15 / MotleyFool.com - Paid Partner Content |
| Previous close | 25.76 |
| Today’s open | 25.61 |
| Day’s range | 24.61 - 25.71 |
| Volume | 692,109 |
| Average volume (3 months) | 892,103 |
| Market cap | $1.9B |
| Earnings growth (last year) | +490.63% |
| Earnings growth (this year) | +40.23% |
| Earnings growth (next 5 years) | +5.91% |
| Revenue growth (last year) | +0.16% |
| P/E ratio | 88.5 |
| Price/Sales | 3.48 |
| Price/Book | 1.94 |
| Today’s change | Today’s % change | |
|---|---|---|
| --Quidel Corp | -0.02 | -0.03% |
| QDELQuidel Corp | +0.92 | +1.65% |
| CDNACareDx Inc | -0.78 | -2.29% |
| VCYTVeracyte Inc | +0.10 | +0.41% |
| Next reporting date | August 22, 2019 |
| EPS forecast (this quarter) | $0.47 |
| Annual revenue (last year) | $772.6M |
| Annual profit (last year) | $131.1M |
| Net profit margin | 16.97% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Mark C. Capone |
Executive Vice President- International Operations Gary A. King |
Corporate headquarters Salt Lake City, Utah |
